Bobby Gaspar, Orchard Therapeutics CEO

FDA green­lights Or­chard's gene ther­a­py Len­meldy for rare and fa­tal dis­ease

The FDA ap­proved a gene ther­a­py known as Len­meldy for ear­ly-on­set metachro­mat­ic leukody­s­tro­phy, or MLD, a rare and fa­tal ge­net­ic dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA